Update on Clinical Plans

Oxford Biomedica PLC
08 November 2002

For immediate release
8 November 2002

                              OXFORD BIOMEDICA PLC

                         UPDATE ON CANCER CLINICAL PLANS


Oxford, United Kingdom - 8 November 2002. Oxford BioMedica plc (LSE:OXB) is
holding an analysts meeting today at its premises on the Oxford Science Park. At
the meeting the Company is reviewing its major programmes in cancer, Parkinson's
disease and vision-loss. As part of the meeting, the Company is describing
clinical development plans for its two cancer products TroVax(R) and MetXia(R).

TroVax(R) will continue to be developed for the lucrative colorectal cancer
market alongside current chemotherapy, 5FU plus Irinotecan and 5FU plus
Oxaliplatin. It is expected that Phase II studies will be complete by the end of
2003 and the product will be ready for Phase III trials at that time. In
addition TroVax(R) will enter, during 2003, three further Phase II trials in
order to broaden the potential indications for the product. The three areas will
be colorectal cancer without chemotherapy, metastatic renal cancer and breast
cancer. These programmes will expand considerably the body of data to support
the notion that TroVax(R) will be used as a cancer product for many tumour
types, a notion predicted by the fact that the tumour antigen that is delivered
by TroVax(R) is found on more than 75% of human solid tumours.

MetXia(R) is expected to complete its second 'high dose' Phase I/II study by the
end of H1 2003 and then will be ready to enter Phase II studies in a number of
disseminated but accessible cancers. In addition the product is planned to enter
trials for pancreatic cancer by the end of 2003. The pancreatic cancer trials
are designed to roll into a Phase II study and should make the product ready for
Phase III trials by late 2004. As with TroVax(R) this will broaden the
commercial potential of MetXia(R) considerably.

The Phase II studies described at the meeting do not change the Company's
overall funding requirements. The Company's planned expenditures can be met from
existing cash resources into late 2004 at least. The Phase II trials may be used
to apply for accelerated approval if the data justify it.

The clinical plans for MetXia(R) are being presented at the Annual Meeting of
the American Association of Pharmaceutical Scientists in Toronto on November
13thby Dr. Susan Kingsman, Oxford BioMedica's Senior Vice President for
Research.

Commenting on the developments Chief Executive Prof. Alan Kingsman said

'We are very pleased with the way that TroVax(R) and MetXia(R) have performed in
the clinic so far. The definition of the clinical development plans for these
products marks another key step in Oxford BioMedica becoming a development stage
Company'.


For further information, please contact:

Oxford BioMedica plc
Professor Alan Kingsman, Chief Executive                Tel: [phone]

City/Financial Enquiries:
Mike Wort, James Chandler: Beattie Financial            Tel: [phone]

Scientific/Trade Press Enquiries:
Sue Charles, Katja Stout: Charles Consultants           Tel: [phone]



                                     -Ends-


Notes to Editors

1.       Oxford BioMedica plc

Established in 1995 as a spin out from Oxford University, Oxford BioMedica is an
international biotechnology company with a diverse portfolio of products and
technology, specialising in gene-based products and technology in the areas of
cancer, neurological disease, cardiovascular disease and blood disorders. This
is underpinned by over 70 patent families, about quarter of which are issued.
Oxford BioMedica plc was floated on the Alternative Investment Market of the
London Stock Exchange in December 1996, and was promoted to the United Kingdom
Listing Authority Official List in April 2001 following a successful £35.5
million fund-raising.

Oxford BioMedica is headquartered in Oxford, UK and has a wholly-owned
subsidiary in San Diego, USA

Currently Oxford BioMedica has corporate collaborations with Aventis, IDM,
Amersham, Valentis, Virbac and Wyeth. BioMedica has two products in Phase I/II
clinical trials: MetXia(R) for late-stage breast cancer, and TroVax(R) for
late-stage colorectal cancer.

2.       World Wide Web

Further information is available on the World Wide Web at 
http://www.oxfordbiomedica.co.uk.


                      This information is provided by RNS
            The company news service from the London Stock Exchange